SCHEMBL3829233

SCHEMBL3829233

Cc1ccc2cnc(-c3c(C)cccc3C)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.43
CYP2A6 P11509 4/20 0.43
MAP4K1 Q92918 2/20 0.43
TDP1 Q9NUW8 1/20 0.39
FGFR1 P11362 1/20 0.39
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
CCR1 P32246 2/20 0.37
CCR5 P51681 2/20 0.37
CCR8 P51685 2/20 0.37
ALDH1A1 P00352 3/20 0.37
NCK1 P16333 1/20 0.37
BACE1 P56817 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831108 0.93 CYP2A6 (0.45) CYP1A2CYP2A6MAP4K1TDP1FGFR1
SCHEMBL3831411 0.81 CASP3 (0.50) CYP1A2CYP2A6MAP4K1TDP1CASP3
SCHEMBL3831280 0.77 ALDH1A1 (0.44) MAP4K1CASP3SENP7ALDH1A1KDM4E
SCHEMBL22431434 0.75 CCR1 (0.65) CYP2A6CCR1CCR5CCR8ALDH1A1
SCHEMBL24756252 0.75 CYP2A6 (0.46) CYP1A2CYP2A6TDP1CASP3SENP7
SCHEMBL3826324 0.75 L3MBTL1 (0.50) CYP1A2CYP2A6MAP4K1TDP1CASP3
SCHEMBL24450787 0.74 NOS3 (0.46) CYP1A2CYP2A6MAP4K1FGFR1CCR1
SCHEMBL14505861 0.72 NPC1 (0.58) CYP1A2CYP2A6TDP1CASP3SENP7
SCHEMBL3831362 0.72 NPC1 (0.51) CYP1A2CYP2A6TDP1CASP3SENP7
SCHEMBL3826128 0.72 CASP3 (0.72) CYP1A2CYP2A6TDP1CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099765-A2 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS Rexahn Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
WO-2008063548-A2 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS REXAHN PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed